Pfizer Inc. (PFE) Return on Equity (ROE): 8.31%
Is Pfizer Inc.’s return on equity (ROE) high or low?
Pfizer Inc.'s return on equity (ROE) of 8.31% is 48% below its 5-year average of 16.07%, near the low end of its 5-year range (2.40%–32.79%).
As of Thursday, June 11, 2026. 8.08% below its 12-month average of 9.04%.
PFE Return on Equity (ROE) Chart
PFE Average Return on Equity (ROE) Chart
PFE Current vs Average Return on Equity (ROE) Chart
PFE Return on Equity (ROE) Metrics
RETURN ON EQUITY (ROE)
8.31%
RETURN ON EQUITY (ROE) AVG TTM
9.04%
RETURN ON EQUITY (ROE) AVG 3Y
13.32%
RETURN ON EQUITY (ROE) AVG 5Y
16.07%
RETURN ON EQUITY (ROE) AVG 10Y
17.51%
RETURN ON EQUITY (ROE) AVG 15Y
15.79%
RETURN ON EQUITY (ROE) AVG 20Y
15.04%
CURRENT VS TTM AVG
-8.08%
CURRENT VS 3Y AVG
-37.60%
CURRENT VS 5Y AVG
-48.30%
CURRENT VS 10Y AVG
-52.53%
CURRENT VS 15Y AVG
-47.37%
CURRENT VS 20Y AVG
-44.74%
PFE Competitors' Return on Equity (ROE)
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pfizer Inc. (PFE) | $149.61B | 8.31% | 9.04% | 13.32% | 16.07% |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 17.05% | 15.07% | 13.91% | 13.46% |
| Abbott Laboratories (ABT) | $155.75B | 12.06% | 20.32% | 18.59% | 17.97% |
| Gilead Sciences, Inc. (GILD) | $156.35B | 39.19% | 20.05% | 21.63% | 19.46% |
| CVS Health Corporation (CVS) | $126.70B | 3.79% | 4.23% | 6.35% | 7.74% |
| Danaher Corporation (DHR) | $126.39B | 6.97% | 7.38% | 9.51% | 10.24% |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 13.21% | 12.70% | 13.51% | 15.24% |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 36.25% | -8.30% | 7.76% | 4.45% |
| Amgen Inc. (AMGN) | $188.37B | 84.87% | 79.33% | 111.35% | 101.76% |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 22.41% | 8.96% | 15.60% | 19.47% |
Return Analysis
ROE
8.3%
ROA
3.6%
Pfizer Inc. Return on Equity (ROE) Formula & Definition
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Pfizer Inc. Return on Equity (ROE) FAQ
- What is the return on equity (ROE) for Pfizer Inc. (PFE)?
- The return on equity (ROE) for PFE stock is 8.31%.
- Is Pfizer Inc.'s return on equity (ROE) high or low?
- Pfizer Inc.'s return on equity (ROE) of 8.31% is 48% below its 5-year average of 16.07%, near the low end of its 5-year range (2.40%–32.79%).
- What is the TTM average return on equity (ROE) for Pfizer Inc. (PFE)?
- The TTM average return on equity (ROE) for PFE stock is 9.04%.
- What is the 3Y average return on equity (ROE) for Pfizer Inc. (PFE)?
- The 3Y average return on equity (ROE) for PFE stock is 13.32%.
- What is the 5Y average return on equity (ROE) for Pfizer Inc. (PFE)?
- The 5Y average return on equity (ROE) for PFE stock is 16.07%.
- What is the 10Y average return on equity (ROE) for Pfizer Inc. (PFE)?
- The 10Y average return on equity (ROE) for PFE stock is 17.51%.
- What is the 15Y average return on equity (ROE) for Pfizer Inc. (PFE)?
- The 15Y average return on equity (ROE) for PFE stock is 15.79%.
- What is the 20Y average return on equity (ROE) for Pfizer Inc. (PFE)?
- The 20Y average return on equity (ROE) for PFE stock is 15.04%.
Pfizer Inc. Return on Equity (ROE) History
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 8.99% |
| 2024-12-31 | 9.09% |
| 2023-12-31 | 2.40% |
| 2022-12-31 | 32.79% |
| 2021-12-31 | 28.69% |
| 2020-12-31 | 14.48% |
| 2019-12-31 | 25.77% |
| 2018-12-31 | 17.59% |
| 2017-12-31 | 29.88% |
| 2016-12-31 | 12.12% |
| 2015-12-31 | 10.76% |
| 2014-12-31 | 12.73% |
| 2013-12-31 | 15.27% |
| 2012-12-31 | 12.04% |
| 2011-12-31 | 10.59% |
| 2010-12-31 | 9.42% |
| 2009-12-31 | 9.59% |
| 2008-12-31 | 13.94% |
| 2007-12-31 | 12.63% |
| 2006-12-31 | 15.45% |
| 2005-12-31 | 11.60% |
| 2004-12-31 | 16.60% |
| 2003-12-31 | 5.98% |
| 2002-12-31 | 45.74% |
| 2001-12-31 | 42.57% |
| 2000-12-31 | 23.18% |
| 1999-12-31 | 35.77% |
| 1998-12-31 | 38.04% |
| 1997-12-31 | 27.90% |
| 1996-12-31 | 27.74% |
Related Metrics
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Albert Bourla